The CDC25B dual speci®city phosphatase is involved in the control of the G2/M transition of the cell cycle. Subcellular localization might represent an important aspect of the regulation of its activity. We have examined in transiently transfected asynchronous HeLa cells the localization of HA-tagged CDC25B proteins and found that they are nuclear or cytoplasmic suggesting the existence of an active shuttling. Accordingly, localization analysis of deletion and truncation proteins indicates that CDC25B contains a putative nuclear localization signal located between residues 335 and 354. We also demonstrated that a short 58 residues deletion of the amino-terminus end of CDC25B is sucient to retain it to the nucleus. Mutational analysis indicates that a nuclear export sequence is located between residues 28 and 40. In addition, treatment of the cells with the exportin inhibitor, Leptomycin B, has the same eect. The mutation of Ser-323, a residue that is essential for the interaction with 14-3-3 proteins, also abolishes cytoplasmic staining. The subcellular localization of CDC25B is therefore dependent on the combined eects of a nuclear localization signal, a nuclear export signal and on the interaction with 14-3-3 proteins.
Introduction
The eukaryotic cell cycle is controlled by members of the well-known CDK (cyclin-dependent kinase) family. The CDC2 protein kinase was the ®rst member identi®ed in yeast where its function is required both at the G1 to S phase and G2 to M phase transition. Homologous and related kinases were subsequently found in every eukaryotic organism and it was demonstrated that they control the key cell cycle events. The regulation of the kinase activity of these proteins is achieved through (i) their association with a cyclin regulatory subunit; (ii) their interaction with CKI (cyclin-dependent kinase inhibitors); and (iii) cycle of phosphorylation and dephosphorylation (Morgan, 1995) . Our knowledge of the kinases and phosphatases that regulate the activity of CDC2 also largely bene®ted from the studies performed in yeast. For instance, CDC25 was ®rst identi®ed in Schizosaccharomyces pombe as a dose dependent activator of mitosis (Russell and Nurse, 1986) . CDC25 is a dual speci®city phosphatase that directly activates the CDC2 kinase at the G2/M transition by dephosphorylating tyrosine 15 and threonine 14 (Morgan, 1995) . On the contrary, these residues are phosphorylated by the WEE1/MIK1 and the MYT1 kinases. In yeast there is only one form of CDC25 while in vertebrate cells three CDC25 phosphatases have been identi®ed (Galaktionov and Beach, 1991; Nagata et al., 1991; Sadhu et al., 1990) . CDC25C and CDC25B are thought to activate CDK/cyclin complexes at the G2/M transition and CDC25A appears to regulate G1/S complexes (Jessus and Ozon, 1995) .
The exact role of CDC25B is still controversial and a matter of debate. On the basis of antisense oligonucleotides studies, it has been proposed that CDC25B is required for progression in S phase (Garner-Hamrick and Fisher, 1998) . Other reports are more in favour of a role for CDC25B in G2 as a regulator of centrosomal microtubule nucleation (Gabrielli et al., 1996) and as a starter of mitosis (Nishijima et al., 1997) . In favour of this hypothesis is the fact that CDC25B is an unstable protein that is degraded by a proteasome-dependent pathway upon phosphorylation by the CDC2/Cyclin A complex (Baldin et al., 1997a) . Furthermore, ablation of CDC25B by microinjection of speci®c antibodies blocks cell cycle progression by inhibition of entry into mitosis (Lammer et al., 1998) . Using micro injection of GFP tagged form of CDC25 and time-lapse microscopy, Karlsson and co-workers very recently showed that overexpression of CDC25B was more potent than CDC25C in causing premature entry into mitosis (Karlsson et al., 1999) , suggesting that the CDC25B phosphatase has a role in the control of the initiation of mitosis.
Controversial ®ndings have been reported on the localization of CDC25B phosphatase. CDC25B was found to be nuclear in G2 phase and appears to translocate to cytoplasm at prophase (Gabrielli et al., 1996 (Gabrielli et al., , 1997 . In a recent report, it was argued that CDC25B is located in the nucleus in G1 and then in the cytoplasm in S and G2 phases (Karlsson et al., 1999) . We identi®ed the existence of splicing variants of CDC25B in human cells (Baldin et al., 1997b; Forrest et al., 1999) . These isoforms dier by the presence or the absence of two peptides, peptide A (14 residues) and peptide B (41 residues), that are both located in the amino-terminus regulatory region of the phosphatase. It is therefore conceivable that these domains may play a role in the regulation of the CDC25B phosphatase activities and in their subcellular localization. Accordingly, it was suggested by Woo et al. (1999) that CDC25B2 was located in the cytoplasm in G1 and then in the nucleus in S to G2/M phase, while in contrast CDC25B3 was located in both the nucleus and the cytoplasm all along the cell cycle. By contrast, Karlsson's study claims that all three CDC25B variants display similar localization (Karlsson et al., 1999) .
Given the major discrepancies between the results published on that issue, we have examined in HeLa cells the localization of CDC25B protein and the molecular basis of its regulation. We have found that CDC25B is exported from the nucleus by a CRM1/ exportin-dependent mechanism and also requires an intact interaction with 14.3.3 proteins.
Results

Localization of CDC25B
Transiently transfected HeLa cells were used to investigate by indirect immuno¯uorescence with monoclonal anti-HA antibodies the intra cellular localization of epitope-tagged versions of CDC25B wild type and mutant proteins. Figure 1a shows the typical staining that was observed 24 h after transfection with the CDC25B3 variant. About 10 ± 15% of the cells were transfected and expressed the CDC25B3 protein both in the cytoplasm and in the nucleus or alternately only in one of these sub cellular compartments. In order to get a quantitative view of these results, the experiment was repeated ®ve times and more than 200 cells were counted for each independent transfection. As shown in Figure 1b , which summarizes these data, about 25% of cells expressing the CDC25B3 variant displayed a nuclear staining with cytoplasmic exclusion while about 15% presented a cytoplasmic staining with nuclear exclusion. The remaining cells (60%) displayed a cytoplasmic and nuclear staining. In agreement with a recent report (Karlsson et al., 1999) , similar results were obtained with the two other splice variants of CDC25B (not shown).
Nuclear localization of CDC25B3 is dependent on a nuclear localization signal
The CDC25B3 sequence contains a putative bipartite nuclear localization signal that is located between residues 335 and 353 (Figure 2a) . To address the role of that region in the subcellular localization of CDC25B3, we made use of truncation and deletion mutants that were transfected in HeLa cells. In agreement with the prediction, we show that an internal deletion of CDC25B (D138 ± 356) that remove this region is sucient to retain the protein in the cytoplasm ( Figure  2b, top panel) . Furthermore, we also demonstrate that truncated proteins 1 ± 251 and 1 ± 311 that comprise only the amino-terminal domain of CDC25B are also retained in the cytoplasm. To further substantiate these results we constructed a CDC25B-NLS mutant in which the KRR motif (residues 350 ± 352) was substituted for AGA. As shown in Figure 2c ,d, this mutant protein was only localized in the cytoplasm of the transfected HeLa cells. We can conclude from these experiments that the putative NLS is functional and is essential for the nuclear localization of CDC25B.
Nuclear exclusion of CDC25B is dependent on a nuclear export signal
We performed a search for a nuclear export sequence (NES) in CDC25B. Examination of CDC25B3 sequence reveals two leucine rich domains in the aminoterminus end of CDC25B3 between residues 29 ± 40 (LPGLLLGSHGLL) and residues 55 ± 67 (LTQTMH-DLAGLGS). These two sequences only partially match the canonical L(X) 2 ± 3 L(X) 2 ± 3 LXL motif for NES (Bogerd et al., 1996; Wen et al., 1995) but a number of variations on this initial theme have already been reported (Yan et al., 1998) . In addition, alignment with a number of CDC25 proteins from other species including Xenopus, in which a functional NES has been identi®ed (Yang et al., 1999) , reveals that both domains encompass evolutionary conserved residues and that the ®rst one aligns with the Xenopus CDC25C NES (see Figure 3a) .
In order to test the hypothesis that CDC25B3 could contain a functional NES, we made use of mutant proteins that were truncated in the amino-terminus end. As shown in Figure 3b ,c, deletion of 58 residues was sucient to retain CDC25B3 in the nucleus of about 75% of the cells as compared to about 25% with wild type CDC25B3. Larger deletion had a similar and even stronger eect. In every case, no cells expressing truncated forms of CDC25B3 displayed exclusively cytoplasmic staining. Two residues whose mutation abolished Xenopus CDC25 nuclear export are indicated in Figure 3a . We mutated the corresponding Leu-34 and Ser-36 residues in human CDC25B and examined the subcellular localization of that mutant protein. As reported in Figure 3c , in about 75% of the cells L34A-S36A-CDC25B3 displayed an exclusive nuclear localization.
Leptomycin B (LMB) is an inhibitor of exportin/ CRM1 that is involved in nuclear export (Kudo et al., 1997 (Kudo et al., , 1998 (Kudo et al., , 1999 Nishi et al., 1994) . We tested the eect of LMB by adding it to HeLa cells that were transiently transfected to express CDC25B3 and mutants. As illustrated in Figure 4a and quantitated Figure 4b , treatment with LMB caused full length CDC25B3 to accumulate in the nucleus. The proportion of exclusively nuclear staining cells increasing from 25% in controls to 80% in the LMB treated cells. A low number of cells displayed a uniform cytoplasm and nuclear staining (decreased from 60% in controls to 20% with LMB treatment), but there were no cells with an exclusive cytoplasmic staining. We could not detect any dierence in the subcellular localization of the truncated versions of CDC25B3 which had the putative NES deleted, in this assay. These results indicate that the localization of CDC25B3 is regulated by nuclear export and together with the results obtained with the truncated and point mutants suggest that an essential determinant for such regulation is located in the ®rst 43 residues of the protein and involve both Leu-34 and Ser-36.
Mutation of S323 abolishes cytoplasmic localization of CDC25B3
It has been proposed that the interaction between CDC25 and members of the 14-3-3 family is an essential process in the regulation of the G2/M checkpoint that is activated by DNA damages or unreplicated DNA. We recently demonstrated that mutation of Ser-323 is sucient to abolish the interaction between CDC25B and the 14-3-3 proteins (Mils et al., 2000) . We therefore wished to examine whether that interaction was involved in the cytoplasmic localization of CDC25B. The localization of a Ser-323-Gly mutant was therefore investigated using both full size CDC25B and a truncated version of CDC25B that lacks the 242 ®rst residues. As shown in Figure 5a , both proteins were located in the nucleus. A statistical analysis of the results (Figure 5b) indicates that with both DN242-S323G and S323G-CDC25B mutants more than 92% of the cells displayed an exclusive nuclear localization and none of them displayed an exclusive cytoplasmic staining. Similarly, mutation of S323 to either Ala, or Glu did not alter the exclusive nuclear localization of CDC25B (data not shown). Thus, interaction of CDC25B with 14-3-3 proteins appears to be essential for its cytoplasmic localization.
CDC25B3 does not interact with cyclin B
Since it has recently been suggested that cyclin B could also participate to CDC25B export (Karlsson et al., 
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S-labelled epitope-tagged CDC25B3 was immunoprecipitated from pcDNA 3 -HA-CDC25B3 transfected cells using anti-HA antibodies but not from mock cells transfected with the pcDNA 3 -HA vector. In contrast, endogenous cyclin B was immunoprecipitated from both CDC25B3 and control transfected cells (Figure 6 ). However, no coimmunoprecipitation of cyclin B and CDC25B3 was detected in the transfected cells.
Discussion
In this work we have investigated the molecular basis of the regulation of CDC25B3 subcellular localization. Our results indicate that CDC25B3 is located either in the cytoplasm or in the nucleus and that this localization is dependent on (i) a nuclear localization sequence; (ii) a nuclear export signal; and (iii) the interaction with 14-3-3 proteins.
CDC25B contains a nuclear localization signal
We have shown here that the nuclear localization of CDC25B3 is dependent on the presence of a putative NLS that is located in the region between residues 311 and 356. This domain encompasses a canonical bipartite nuclear localization sequence and is identical to the Xenopus CDC25 NLS (Yang et al., 1999) . To support that conclusion, we have shown that a deletion of residues 138 to 356 is sucient to abrogate CDC25B3 nuclear localization and that the aminoterminal domain (residues 1 ± 251 and 1 ± 311) do not contain the molecular determinant for nuclear targeting. Furthermore, point mutagenesis of the KRR motif was sucient to fully abolish nuclear import thus indicating that the NLS is functional.
CDC25B does have a functional NES
Here we report that CDC25B3 localization is dependent on a nuclear export mechanism that is inhibited by Leptomycin B, a speci®c inhibitor of exportin/CRM1 (Kudo et al., 1998 (Kudo et al., , 1999 . We also show that an aminoterminus deletion of CDC25B3 is sucient to abrogate CDC25B3 export. Although, it is not a canonical motif (Bogerd et al., 1996) , we have found that a putative NES is located in that region of the protein and that point mutations of Leu34 and Ser36 had a similar inhibitory eect on nuclear export of CDC25B3. This eect was only partial with about 75% of cells displaying an exclusively nuclear localization as compared to 25% with the wild type protein, suggesting that additional residues might also participate to the export process. In support to our hypothesis, that region is conserved with Xenopus CDC25 where its mutation also abolishes nuclear export (Yang et al., 1999) . Thus in contrast to what was argued by Karisson et al. (1999) , we propose that CDC25B possess its own nuclear export signal and is exported independently of cyclin B. Figure 3 The amino-terminus of CDC25B contains a putative NES. (a) Alignment of the amino-terminus end of the Xenopus CDC25 and the human CDC25B sequences. Identical and conserved residues are indicated in black and grey background respectively. Two leucine rich domains that at least partially match the nuclear export signal consensus sequence are underlined twice. The ®rst domain aligns with the one identi®ed in Xenopus CDC25 and the two residues whose mutation abolished nuclear export are indicated with a star (Yang et al., 1999) . Several evidences are in favour of our hypothesis. In our work CDC25B3 was expressed to a level that is at least one order of magnitude in excess to the cyclin B level (data not shown). It is therefore unlikely that every CDC25B3 molecule could interact with a cyclin B partner to be eciently exported from the nucleus. Accordingly, in our experimental conditions, CDC25B3 and cyclin B pull down experiments from CDC25B3 transfected cells did not reveal any association with cyclin B (Figure 6 ). Although we are not excluding an interaction between these proteins, the amount of complex between CDC25B and cyclin B is probably very minor in regard to the total amount of CDC25B3 in transfected cells. Thus our results suggest that dierent mechanisms may be involved in the nuclear export of CDC25B3 and cyclin B.
Interaction with 14-3-3 proteins is required for cytoplasmic localization of CDC25B3
Several recent reports have demonstrated that S216 in human CDC25C is a major determinant of the interaction with 14-3-3 proteins. We have recently shown that S323 (the homologue of S216 in CDC25C) is a major 14-3-3 binding site in CDC25B, and that the S323G-CDC25B3 mutant is unable to interact with 14-3-3 proteins (Mils et al., 2000) . As reported here, that mutation abolished cytoplasmic localization of CDC25B3. In the case of the deletion of the NES containing domain, 75% of cells displayed a nuclear CDC25B3 localization and the additional mutation of S323 was sucient to fully retain CDC25B3 in the nucleus. Thus, the interaction of CDC25B3 with 14-3-3 appears to be an essential parameter regulating its subcellular localization. These results are in agreement with the data of Dalal et al. (1999) who demonstrate that the cytoplasmic localization of human CDC25C requires an intact 14-3-3 binding site. In Xenopus, Kumagai and Dunphy (1999) also demonstrated that the interaction of CDC25 with 14-3-3 epsilon provokes the cytoplasmic retention of CDC25. Similarly, in ®ssion yeast, cdc25 is exported from the nucleus by binding to the rad24 14-3-3 protein (Lopez-Girona et al., 1999) .
An alternative possibility is, as suggested from the work performed on Xenopus CDC25 (Kumagai and Dunphy, 1999; Yang et al., 1999) , that 14-3-3 binding inhibits nuclear import of CDC25B3 by masking the NLS or preventing the interaction with importins. The mutation of Ser-323 may then unmask the strong NLS, leading to a shift of the balance towards nuclear import.
Thus, it appears that interaction between CDC25 phosphatases and members of the 14-3-3 family is probably a common feature in the regulation of the subcellular localization of these enzymes.
In conclusion, we propose a working model to summarize our results (Figure 7) . The NLS and the NES of CDC25B3 that we have identi®ed are responsible of the nucleo-cytoplasmic shuttling of the protein. Mutation of either of these two domains aects the localization of CDC25B, which is then fully cytoplasmic or fully nuclear respectively. In this model, interaction with 14-3-3 protein is dependent on a modi®cation of CDC25B3 occurring in the nucleus or immediatly upon nuclear export. This modi®cation could for instance be a phosphorylation event by a kinase such as the c-TAK1 kinase (Peng et al., 1998) , a checkpoint kinase (Matsuoka et al., 1998; Sanchez et al., 1997) , or the interaction with another regulatory partner.
Materials and methods
Cell culture and transfection
HeLa cells, obtained from the American Type Culture Collection, were cultured in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% heat inactivated foetal calf serum (Eurobio), 2 mM glutamine, penicillin (100 U/ml) and streptomycin (100 mg/ml) in a humidi®ed atmosphere containing 5% CO 2 at 378C.
Transfections were achieved using linear ethylenimin polymers (PEI) (EXGEN 500, Euromedex) according to the instruction of the manufacturer using 2 mg of puri®ed plasmid. The transfection eciency was usually in the range of 10 ± 15%. For the experiment reported in Figure 2b , HeLa cells were transfected by electroporation.
For the indicated experiments, transfected cells were treated with Leptomycin B (20 ng/ml) during 2 h before ®xation.
Immunofluorescence
Twenty-four hours after transfection, cells grown on glass coverslips were recovered, washed once with PBS, ®xed in 3.7% formaldehyde in PBS at 48C for 20 min then washed three times with PBS. Cells were then permeabilized with 0.25% Triton X-100 in PBS for 5 min at room temperature and with a further incubation in 100% cold methanol for 10 min at 7208C. Fixed and permeabilized cells were then saturated with 1% BSA in PBS for 15 min at room temperature then washed three times in PBS/BSA. The cells were then incubated for 1 h at 378C with monoclonal anti-HA antibody (kindly provided by P LeÂ opold) diluted 1/800 in PBS/BSA 1%. After three washes with PBS/BSA 1%, the cells were incubated with Alexa 594-conjugated goat antimouse antibodies (Molecular Probes) diluted in PBS/BSA 1% for 45 min at room temperature, washed in PBS/BSA 1% and ®nally incubated with Hoechst 1 mg/ml for 10 min at room temperature. Coverslips were washed with PBS and mounted in Mowiol. For the experiments reported in Figure  2 , staining was performed using an anity puri®ed antibody raised against CDC25B3 1 ± 311 (Gabrielli et al., 1996) . Cells were counter stained for DNA using propidium iodide.
Microscopic examination were performed under a Leica photomicroscope. Pictures were taken on Kodak Tmax 400 ®lms. All the experiments were repeated at least three times and a minimum of 200 transfected cells were examined for each independent experiments. The statistical analysis were performed as following: SD=H(S(x ± m) 2 /(n ± 1)) and s.e.m.=s.d./Hn where m is the percentage mean value and n the number of experiments.
Plasmids construction
To produce CDC25B 1-251, pUCSRa CDC25B3 (Gabrielli et al., 1996) was digested with AvrII and the 1.2 kb AvrII/AvrII fragment was ligated into AvrII/XbaI digested pUCSRa in the orginal orientation. CDC25B 1-311 was produced by removing the BsrG1/XhoI fragment from pUCSRa CDC25B3 containing the 3' end of CDC25B3 coding region and 3'UTR. The remaining fragment was end ®lled and religated. The S-methionine/cystein was carried out for 2 h. Immunoprecipitations were performed using anti-HA (for CDC25B3) or anti-cyclin B polyclonal antibodies and the samples were run on SDSpolyacrylamide gel electrophoresis prior to autoradiography. In vitro translated 35 S-methionine-labelled CDC25B3 and cyclin B are shown in the two ®rst lines as control Figure 7 Current working model for the nucleo-cytoplasmic shuttling of CDC25B. CDC25B is ®rst targeted to the nucleus in a NLS-dependent manner. Export to the cytoplasm is dependent on the amino-terminal nuclear export signal (NES). We propose that post-translational modi®cations occurring in the nucleus or after nuclear export allow the interaction with 14-3-3 proteins that is essential to trap CDC25B in the cytoplasm (see text for more details) CDC25B subcellular localization N Davezac et al internal truncation of residues 138 ± 356 from CDC25B3 (CDC25B D138 ± 356) was produced by sequential digestion of pSVK3 CDC25B3 (Gabrielli et al., 1996) with BstB1 then Bsu361 to remove a 0.66 kb fragment of the coding region, the 5' overhangs ®lled and religated. The CDC25B D138 ± 356 was subcloned into pUCSRa by excising the XhoI/XbaI fragment from pSVK3 into the corresponding sites in pUCSRa.
Other plasmids were constructed using the pcDNA 3 -HA vector and DNA inserts from wild type and mutants CDC25B3 cDNA that have been described elsewhere (Mils et al., 2000) . The triple HA-tag was placed in frame with the coding sequences at their amino-terminal end. The residues numbering that are given in this study do not take into account these additional 20 amino-acids and only refer to the sequence from the natural CDC25B initiating codon.
Mutation (L34A-S36A) in the putative NES sequence was generated by PCR on the pcDNA 3 -HA CDC25B3 plasmid using the primer 5' -GGC CTC CTG GCG GGG GCC CAT GGC CTC CTG -3' (sense) and 5' -CAG GAG GCC ATG GGC CCC CGC CAG GAG GCC -3' (antisense), and the Pfu DNA polymerase (Promega).
Metabollc labelling and immunoprecipitation
For metabolic labelling, transiently pcDNA 3 -HA CDC25B3 transfected cells were preincubated 30 min in methionine and cysteine-free DMEM, followed by the addition of [ 35 S]methionine/cysteine (1000 Ci/mmole; Amersham) to a ®nal concentration of 187.5 mCi/ml for 2 h before recovering the cells. Cells were lysed for 30 min at 48C, in lysis buer containing: 50 mM Tris-HCl (pH 7.5), 250 mM NaCl, 5 mM EDTA, 0.1% Triton X-100, 1 mM DTT and protease and phosphatase inhibitors (Baldin et al., 1997a) . Immunoprecipitations were performed using either polyclonal antibodies raised against human cyclin B1 (Baldin, unpublished data) or monoclonal anti-HA antibodies. In vitro transcription and translation of CDC25B3 and cyclin B1 were performed using the TNT quick system (Promega) in the presence of [ 35 S]methionine. Proteins were analysed by electrophoresis on SDS-12.5% polyacrylamide gels and autoradiography.
